brain natriuretic peptide
PreclinicalPeptide
brain natriuretic peptide is one of 10 small molecule programs targeting Angioedema. It is currently in Preclinical.
1
Indications
2
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Angioedema
#DrugCompanyPhaseTrials
1Firazyr
TakedaApproved
Adrenaline
SSamson Clinical Operations Pty Ltd
Approved
Deucrictibant
PPharvaris Netherlands B.V.
Phase 3
Januvia
ZZydus Therapeutics Inc.
Preclinical
Heparin Sodium
BBaxter Healthcare Corporation
Preclinical
Substance P
GSKPreclinical
Glucagon Like Peptide-1
UUniversity Hospital, Gentofte, Copenhagen
Preclinical
Bradykinin
VVanderbilt University
Preclinical
Ekterly
KKalVista Pharmaceuticals, Ltd.
Preclinical
brain natriuretic peptide
MMayo Clinic
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for brain natriuretic peptide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Preclinical[1]
- Company
- MMayo Clinic